Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Horizon Discovery Group PLC    HZD   GB00BK8FL363

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
242(c) 242(c) 225(c) 234(c) 236(c) Last
188 177 195 477 71 370 197 026 180 742 Volume
+7.08% 0.00% -7.02% +4.00% +0.85% Change
More quotes
Financials ( GBP)
Sales 2017 36,3 M
EBIT 2017 -8,08 M
Net income 2017 -7,15 M
Finance 2017 23,5 M
Yield 2017 -
Sales 2018 64,9 M
EBIT 2018 1,70 M
Net income 2018 0,20 M
Finance 2018 5 823 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 985,26
EV / Sales2017 8,97x
EV / Sales2018 -84,3x
Capitalization 349 M
More Financials
Company
Horizon Discovery Group Plc is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health.It serves pharmaceutical, biotechnology and diagnostic companies.The company was founded by Christopher John... 
More about the company
Surperformance© ratings of Horizon Discovery Group PL
Trading Rating : Investor Rating :
More Ratings
Latest news on HORIZON DISCOVERY GROUP PL
2017 HORIZON DISCOVERY : expands agreement with Roche Diagnostics
2017 HORIZON DISCOVERY : enters into agreement with Roche Diagnostics to support the ..
2017 HORIZON DISCOVERY : Agreement with Roche Diagnostics
2017 HORIZON DISCOVERY : introduces Multiplex cfDNA Reference Standard for EGFR mutat..
2017 HORIZON DISCOVERY : extends industry-leading gene editing IP portfolio through e..
2017 HORIZON DISCOVERY : HZD expand CRISPR license rights with ERS Genomics
2017 HORIZON DISCOVERY : Structural Multiplex Reference Standard now available in FFP..
2017 HORIZON DISCOVERY : Dharmacon introduces Edit-R CRISPRa reagent platform for gen..
2017 HORIZON DISCOVERY : partners with The Michael J. Fox Foundation for Parkinsons r..
2017 HORIZON DISCOVERY : partners with The Michael J. Fox Foundation to introduce nov..
More news
Sector news : Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
2017$HZD - Numis Securities Reaffirms "Buy" Rating for Horizon Discovery Group #H.. 
2017Horizon Discovery Group's buy rating reiterated at Numis Securities Ltd. GBX .. 
2017Horizon Discovery : enters into agreement with Roche Diagnostics to support t.. 
2017Horizon Discovery : extends industry-leading gene editing IP portfolio throug.. 
2017Horizon Discovery : HZD expand CRISPR license rights with ERS Genomics  
More tweets
Qtime:26
Chart HORIZON DISCOVERY GROUP PL
Duration : Period :
Horizon Discovery Group PL Technical Analysis Chart | HZD | GB00BK8FL363 | 4-Traders
Technical analysis trends HORIZON DISCOVERY GROUP PL
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 2,73  GBP
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Darrin Matthew Disley President, CEO & Executive Director
Ian David Gilham Non-Executive Chairman
Richard John Vellacott CFO, Secretary & Executive Director
Jürgen Harter Global Head-IT & Informatics
Jonathan D. Moore Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
HORIZON DISCOVERY GROUP PLC-2.50%485
CELLTRION, INC.--.--%37 510
IQVIA HOLDINGS INC2.37%20 782
LONZA GROUP0.76%20 640
INCYTE CORPORATION-4.65%19 399
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 192